Feature|Articles|August 14, 2026

The 2026 GLP-1 Compounding Crackdown: A Pharmacist’s Guide

The year 2026 has brought a stark paradox to American pharmacy practice, and it’s affecting the most sought-after prescription drugs on the market.

Although the supply chain for glucagon-like peptide-1 (GLP-1) blockbusters like semaglutide and tirzepatide has stabilized and shortages have resolved, the parallel economy of compounded alternatives remains highly active, leaving pharmacists on the front lines of safety and regulatory battles.^1,2